Who can take part?

Patients with Muscle-invasive Bladder Cancer.

What is involved for you?

Patients in the trial may receive the investigational product  enfortumab vedotin (EV) + pembrolizumab (pembro) or receive standard chemotherapy gemcitabine + cisplatin  before having surgery to remove the bladder. Patients who are having the experimental treatment will continue to receive enfortumab vedotin (EV) + pembrolizumab (pembro) after surgery.  During visits to the clinic all participants will have physical assessments, blood tests and scans to assess the status of the tumour.